Mary Wilson
Well-known member
New lineage proposal
by @corneliusroemer
Description
Sub-lineage of: AY.4
Earliest sequence: UK 2021-23
Most recent sequence: Current
Countries circulating: Mostly UK (now 5%), also Denmark at 1-2% and other European countries
Lineage deriving from AY.4 with extra Spike mutations S:Y145H and S:A222V. It has a pretty steady growth rate in the UK over the past weeks which could be indicative of a real fitness advantage as opposed to a chance event (founder effect).
If we want to cast the net wide, the first mutation in addition to AY.4 was T17040C (synonymous). But since it's synonymous, it probably doesn't makes more sense to make the 2 spike mutations defining.
...
https://github.com/cov-lineages/pango-designation/issues/223
______________________________________________________________________
David States
Chief Science/Medical Officer Angstrom Bio, Austin, TX Comments and opinions my own. COI: Our company is developing high throughput diagnostics for COVID-19
Ann Arbor, MI and Austin, TX
COVID19 Retweeted
Not looking good for the hope that delta + S:Y145H is just a founder effect or fluctuation, its prevalence continues to increase in the UK, now up to ~8%. Only a matter of time before this hits the US and rest of the globe
https://twitter.com/statesdj/status/1449105999198101510
by @corneliusroemer
Description
Sub-lineage of: AY.4
Earliest sequence: UK 2021-23
Most recent sequence: Current
Countries circulating: Mostly UK (now 5%), also Denmark at 1-2% and other European countries
Lineage deriving from AY.4 with extra Spike mutations S:Y145H and S:A222V. It has a pretty steady growth rate in the UK over the past weeks which could be indicative of a real fitness advantage as opposed to a chance event (founder effect).
If we want to cast the net wide, the first mutation in addition to AY.4 was T17040C (synonymous). But since it's synonymous, it probably doesn't makes more sense to make the 2 spike mutations defining.
...
https://github.com/cov-lineages/pango-designation/issues/223
______________________________________________________________________
David States
Chief Science/Medical Officer Angstrom Bio, Austin, TX Comments and opinions my own. COI: Our company is developing high throughput diagnostics for COVID-19
Ann Arbor, MI and Austin, TX
COVID19 Retweeted
Not looking good for the hope that delta + S:Y145H is just a founder effect or fluctuation, its prevalence continues to increase in the UK, now up to ~8%. Only a matter of time before this hits the US and rest of the globe
https://twitter.com/statesdj/status/1449105999198101510
